It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Telehealth company Hims & Hers Health Inc. (NYSE: HIMS) was already a thriving platform discretely selling doctor-prescribed sexual health treatment along with prescription hair loss and mental ...

The participants were divided into two groups, with half receiving weekly low-dose injections of semaglutide (Ozempic and Wegovy), a GLP-1 agonist, and the other half getting a placebo shot.

However, the company supercharged its top and bottom line with the addition of compounded semaglutide GLP-1 injections that start at $99 the first month and go up to $199 afterward. Compounded GLP ...